BDTX - NASDAQ
Black Diamond Therapeutics, Inc.
$2.10
-7.1%Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotBlack Diamond Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Black Diamond Therapeutics, Inc. Income Statement
BDTX • NASDAQ
| Black Diamond Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
70M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||
(325K) | (0.0) | (437K) | (0.0) | (0.0) | (0.0) | (47K) | (44K) | (24K) | |
69.7M | 0.0 | -437K | 0.0 | 0.0 | 0.0 | -47K | -44K | -24K | |
OPERATING INCOME | |||||||||
(49.8M) | (78.8M) | (86M) | (92.8M) | (126.9M) | (69.6M) | (29.3M) | (8.9M) | (4.1M) | |
(16.6M) | (27.5M) | (27.1M) | (28.4M) | (30M) | (21.4M) | (7.6M) | (2M) | (666K) | |
(33.6M) | (51.3M) | (58.9M) | (64.4M) | (96.8M) | (48.2M) | (21.8M) | (7M) | (3.5M) | |
19.9M | -78.8M | -86.5M | -92.8M | -126.9M | -69.6M | -8.9M | -8.9M | -4.1M | |
PRE-TAX INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1K) | (0.0) | (0.0) | (65K) | |
4.1M | 2.2M | 1.9M | 2M | 3.5M | 4M | 0.0 | 0.0 | 0.0 | |
-325K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -16K | -6K | |
2.5M | 9.1M | 4M | 1.7M | 1.3M | 2.3M | -5.9M | -27K | -483K | |
22.4M | -69.7M | -82.4M | -91.2M | -125.6M | -67.3M | -35.3M | -8.9M | -4.6M | |
NET INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (5.9M) | -27K | (0.0) | |
22.4M | -69.7M | -82.4M | -91.2M | -125.6M | -67.3M | -35.3M | -8.9M | -4.6M |
SEC Filings
BDTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 03, 2025 | 2025 | |
S-3 S-3 N/A | November 13, 2025 | November 13, 2025 | ||
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your BDTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.